AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Endonuclease V

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8N8Q3

UPID:

ENDOV_HUMAN

Alternative names:

Inosine-specific endoribonuclease

Alternative UPACC:

Q8N8Q3; I3L3S4; Q6P2G2; Q86X99; Q8NAK0

Background:

Endonuclease V, known for its unique ability to specifically cleave inosine-containing RNAs, plays a pivotal role in RNA metabolism. This enzyme targets RNA by cleaving at the second phosphodiester bond 3' to inosine, showcasing activity against both single-stranded and double-stranded RNAs. Its preference for single-stranded RNAs highlights its specialized function in processing mRNAs and tRNAs that contain inosine, a modification occurring post-transcriptionally in various RNAs.

Therapeutic significance:

Understanding the role of Endonuclease V could open doors to potential therapeutic strategies. Its involvement in RNA editing and processing mechanisms suggests a broader regulatory role, possibly in antiviral responses or RNA stability, offering a novel target for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.